Objective
Cushing’s disease
POLAND
Edited by: Renato Cozzi, Endocrinology Unit Ospedale Niguarda, ItalyReviewed by: Przemyslaw Witek, Warsaw Medical University, Poland; Athanasios Fountas, General Hospital of Athens G. Genimatas, Greece†Present addresses: Alberto M. Pedroncelli, Chief Medical Office, Camurus AB, Lund, SwedenRicardo Maamari, Global Medical Affairs, Mayne Pharma, Raleigh, NC, United States‡These authors have contributed equally to this workThis study evaluated short- and long-term efficacy and safety of the second-generation somatostatin receptor ligand pasireotide alone or in combination with dopamine agonist cabergoline in patients with Cushing’s disease (CD).